Drug Profile
Research programme: ansamycin analogues - Demuris
Alternative Names: Ansamycin Series; DC355B1 series; Kanglemycin ALatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Demuris
- Class Antibacterials; Antituberculars; Rifamycins
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-negative infections; Tuberculosis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Tuberculosis(Treatment-resistant) in United Kingdom
- 28 Dec 2022 No recent reports of development identified for research development in Gram-negative-infections in United Kingdom
- 22 Dec 2020 Early research development is ongoing the United Kingdom